Electrocore Stock Price, News & Analysis

electroCore, Inc. (Nasdaq: ECOR) announced the issuance of four patents by the USPTO related to its non-invasive vagus nerve stimulation (nVNS) technology. These patents enhance their mobile connectivity platform, focusing on treating conditions such as dementia and gastrointestinal disorders. The patents cover:

• nVNS for dementia
• Remote therapy and patient monitoring
• Electrical nerve stimulation for gastrointestinal issues
• Stimulators compatible with mobile devices

CEO Dan Goldberger emphasized the company's commitment to expanding therapeutic applications of nVNS.

electroCore, Inc. (Nasdaq: ECOR) announced its 2022 Annual Meeting of Stockholders scheduled for December 2, 2022, to be held virtually. Proxy materials will be sent in October 2022. Stockholders wishing to submit proposals must notify the Corporate Secretary by September 30, 2022. The company specializes in non-invasive vagus nerve stimulation therapy for treating various headaches. Currently, gammaCore™ is FDA cleared and CE-marked for multiple headache treatments, focusing on improving patient outcomes.

electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed study demonstrating that non-invasive vagus nerve stimulation (nVNS) significantly alleviates opioid withdrawal symptoms in patients with opioid use disorder (OUD). Conducted with the support of Emory and Georgia Tech, the double-blind study involved 21 patients and showed substantial reductions in distress and pain compared to sham treatment. This research highlights the potential for nVNS as a valuable non-pharmacological therapy for OUD, amidst an escalating opioid crisis in the United States.

electroCore, Inc. (Nasdaq: ECOR) announced that CEO Dan Goldberger will participate in two upcoming conferences. The H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 14, 2022, from 12:30 to 1:00 PM EDT, featuring a fireside chat. The Ladenburg Thalmann 2022 Healthcare Conference will take place on September 29, 2022, from 3:30 to 3:55 PM EDT, where Goldberger will present. electroCore is focused on bioelectronic medicine, specializing in non-invasive vagus nerve stimulation therapies for conditions such as migraines and cluster headaches.

electroCore, a bioelectronic medicine company, announced CEO Dan Goldberger's presentation at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 8:30 AM EDT. The conference will be available via webcast. electroCore is focused on non-invasive vagus nerve stimulation therapies for conditions like cluster headaches and migraines.

electroCore reported a record second quarter 2022 net sales of $2.2 million, marking a 70% increase year-over-year and a 14% sequential rise. However, net cash used in operating activities was $3.2 million, with approximately $26.6 million in cash reserves as of June 30, 2022. The company announced its gammaCore nVNS device participation in the Department of Defense BOOST program and an exclusive licensing agreement with Teijin for Japan. Third-quarter revenue is expected to remain stable compared to Q2 2022.

electroCore, Inc. (Nasdaq: ECOR) plans to announce its second quarter financial results for the period ending June 30, 2022, after market close on August 4, 2022. A conference call will follow at 4:30 PM EDT for management to discuss the results and address questions. The company focuses on bioelectronic medicine, particularly through its non-invasive vagus nerve stimulation platform aimed at treating several neurological conditions, including migraines and cluster headaches.

electroCore anticipates record revenue of at least $2.1 million for Q2 2022, representing a 65% increase from Q2 2021. This guidance indicates an 11% rise over Q1 2022 revenue. Key revenue sources include approximately $1.2 million from government channels, $465,000 from commercial sales, and $466,000 from international markets. The company's cash balance at the end of Q2 2022 stands at $26.6 million. A detailed financial update is expected in August.

electroCore (Nasdaq: ECOR) announced that Mayo Clinic is initiating a study on gammaCore Sapphire, a non-invasive vagus nerve stimulation therapy, to evaluate its efficacy in treating post-COVID syndrome. The study aims to enroll up to 20 patients with symptoms persisting over 28 days post-COVID infection. The trial will assess clinical questionnaires and brain metabolism using PET-CT. This follows gammaCore’s past FDA approval for treating migraines and cluster headaches, suggesting its relevance in addressing post-COVID health issues that may affect millions globally.